Disease × agent evidence record

Cinnarizine for Tinnitus: evidence, trials and status

Synthesis-level literature links Cinnarizine to Tinnitus, but no registered trial in this database tests the pair, so the evidence is observational, pooled from other indications, or pre-dates registry practice.

0 registered trials 0 recruiting 10 publications Evidence tier A · Strong Score 45.0
Research Tracker › Pairs › Tinnitus › Cinnarizine
Research map, not treatment advice. This page aggregates registry and literature records. It does not evaluate efficacy, dosing or safety for any individual. Discuss any treatment decision with a qualified clinician.

Summary

Cinnarizine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Tinnitus would be drug repurposing rather than first-in-human development. This does not mean it is approved for Tinnitus. No registered clinical trial in this database tests Cinnarizine specifically in Tinnitus. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 10 publications for this pair: 4 systematic reviews, 1 randomised controlled trial publication and 5 clinical trial publications. Publication years run from 1988 to 2025. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.

The RepurpOS disease-intelligence file for Tinnitus ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous resolution in 50-60% of acute tinnitus (<3 months) without treatment; chronic tinnitus (>3 months): only 10-15% spontaneous resolution; habituated tinnitus (not distressing) in 75% at 5 years but sound remains in most.

Open in Repurposing ExplorerTinnitus hubTinnitus biomarkers & interventions

Evidence table

Evidence tierA · Strong
Evidence score45.0 (trials 0.0, literature 25.0, tier 15, approved bonus 5.0)
Registered trials0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other
Linked publications10 (5 clinical trial publications, 4 systematic reviews, 1 randomised controlled trial publication)
Agent typeDrug (Small molecule)
Development stage (any indication)Approved
Mechanism / classblocker
Data sourcesDGIdb
Linked via biomarker / targetCACNA1F
How the evidence score is calculated
  • Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
  • Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
  • The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
  • Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
  • The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.

Registered clinical trials

No registered trial links Cinnarizine to Tinnitus in the current OSMF trial extract.

Search ClinicalTrials.gov for newer studies

Published literature

Run the live PubMed search

Mechanism and notes

Recorded mechanism or class: blocker.

OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CACNA1F. The tier describes how well the drug-disease link is documented, not how well the drug works.

Frequently asked questions

Is Cinnarizine approved for Tinnitus?

Cinnarizine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Tinnitus would be drug repurposing rather than first-in-human development. This does not mean it is approved for Tinnitus. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.

Is Cinnarizine in clinical trials for Tinnitus?

No registered clinical trial in this database tests Cinnarizine specifically in Tinnitus. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.

What does the evidence show for Cinnarizine in Tinnitus?

Synthesis-level literature links Cinnarizine to Tinnitus, but no registered trial in this database tests the pair, so the evidence is observational, pooled from other indications, or pre-dates registry practice. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CACNA1F. The tier describes how well the drug-disease link is documented, not how well the drug works.

Cite this page

Open Source Medicine Foundation. Cinnarizine for Tinnitus: evidence, trials and status. OSMF Research Tracker. Updated 2026-07-06. https://research.opensourcemed.info/pairs/tinnitus/cinnarizine.html

Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.

Get OSMF research updates on Substack

This is a research map, not treatment advice. Evidence tiers and scores summarise what has been studied, not whether a treatment works or is safe for you.